194 related articles for article (PubMed ID: 19509244)
1. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
Herberger B; Berger W; Puhalla H; Schmid K; Novak S; Brandstetter A; Pirker C; Gruenberger T; Filipits M
Mol Cancer Ther; 2009 Jun; 8(6):1547-56. PubMed ID: 19509244
[TBL] [Abstract][Full Text] [Related]
2. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Chiu CW; Nozawa H; Hanahan D
J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G
Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914
[TBL] [Abstract][Full Text] [Related]
4. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.
Xie X; Ghadimi MP; Young ED; Belousov R; Zhu QS; Liu J; Lopez G; Colombo C; Peng T; Reynoso D; Hornick JL; Lazar AJ; Lev D
Clin Cancer Res; 2011 Sep; 17(18):5901-12. PubMed ID: 21821699
[TBL] [Abstract][Full Text] [Related]
5. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
6. Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.
Costa LJ; Gemmill RM; Drabkin HA
Urology; 2007 Mar; 69(3):596-602. PubMed ID: 17382186
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
8. Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Jimeno A; Rubio-Viqueira B; Amador ML; Grunwald V; Maitra A; Iacobuzio-Donahue C; Hidalgo M
Mol Cancer Ther; 2007 Mar; 6(3):1079-88. PubMed ID: 17363501
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Li B; Gao S; Wei F; Bellail AC; Hao C; Liu T
Oncol Rep; 2012 Jul; 28(1):15-20. PubMed ID: 22552366
[TBL] [Abstract][Full Text] [Related]
10. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
11. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
[TBL] [Abstract][Full Text] [Related]
12. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
13. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
Jimeno A; Kulesza P; Wheelhouse J; Chan A; Zhang X; Kincaid E; Chen R; Clark DP; Forastiere A; Hidalgo M
Br J Cancer; 2007 Mar; 96(6):952-9. PubMed ID: 17342092
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
15. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.
Rao RD; Mladek AC; Lamont JD; Goble JM; Erlichman C; James CD; Sarkaria JN
Neoplasia; 2005 Oct; 7(10):921-9. PubMed ID: 16242075
[TBL] [Abstract][Full Text] [Related]
16. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
[TBL] [Abstract][Full Text] [Related]
17. Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.
Glaysher S; Bolton LM; Johnson P; Torrance C; Cree IA
BMC Res Notes; 2014 Jun; 7():397. PubMed ID: 24964744
[TBL] [Abstract][Full Text] [Related]
18. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
[TBL] [Abstract][Full Text] [Related]
19. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
